On Thursday, Stifel, a financial services company, updated its outlook on argenx SE (NASDAQ: ARGX) stock, raising the price target to $707 from the previous $604 while maintaining a Buy rating. The revision follows argenx's third-quarter financial update, which exceeded expectations with revenues of $573 million compared to the forecasted $520 million. The performance was attributed to the growth in Myasthenia Gravis (MG) treatments and a successful initiation of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) product launch.
argenx reported that over 300 patients were being treated with efgartigimod by the end of the third quarter in 2024. This number, though slightly lower than the initial MG uptake, aligns with the company's projections. Stifel has adjusted their model to reflect this growth trajectory, which was initially expected to be more rapid.
The company's pipeline continues to advance, particularly with Empasiprubart, which is scheduled to enter Phase 3 trials for Multifocal Motor Neuropathy (MMN) by the end of the year and has ongoing Proof of Concept (PoC) studies for Delayed Graft Function (DGF) and Dermatomyositis (DM), with a pivotal CIDP trial planned for the following year.
Significant pipeline updates expected by the end of 2024 include a decision on whether to proceed with Myositis treatments, the commencement of Phase 3 trials for Sjogren's syndrome, and an update on Bullous Pemphigoid treatments. In addition, ARGX-119 has entered PoC studies, contributing to the company's growing research and development efforts.
Stifel's analyst highlighted that while the market's attention is largely focused on argenx's commercial execution, the stock price does not fully reflect the value of the company's expanding pipeline. This sentiment underscores the potential for argenx's diverse array of therapeutic candidates beyond the already successful efgartigimod.
In other recent news, argenx SE recorded a substantial second-quarter revenue of $489 million in 2024, primarily driven by net sales from Vyvgart. This robust performance exceeded consensus estimates, prompting Baird to revise its price target for argenx to $515 and maintain an Outperform rating. Barclays also upgraded argenx stock from Equalweight to Overweight, emphasizing Vyvgart's promising future. Wells Fargo and H.C. Wainwright raised their price targets on argenx shares, citing the company's strong revenue growth.
However, Deutsche Bank downgraded argenx stock from Buy to Hold after reviewing Phase 3 ADHERE data, crucial for the company's current CIDP launch. The firm expressed more caution than optimism regarding the CIDP launch, influencing their rating adjustment. On the contrary, Piper Sandler maintained an Overweight rating on argenx shares, expressing confidence in Vyvgart's potential, even amidst potential competition from Amgen (NASDAQ:AMGN)'s Uplizna.
Regarding product development, argenx is advancing with its Immune Thrombocytopenia (ITP) treatment. The company announced plans to proceed with a confirmatory study in the United States, bringing the treatment closer to potential approval and commercial availability. Additionally, argenx recently received CIDP approval and is preparing for the product's launch. These are the latest developments for argenx SE.
InvestingPro Insights
argenx SE's strong financial performance and pipeline developments are reflected in recent InvestingPro data and tips. The company's revenue growth is particularly noteworthy, with a 98.69% increase over the last twelve months as of Q2 2024, reaching $1.66 billion. This aligns with the impressive Q3 results mentioned in the article, which exceeded analyst expectations.
InvestingPro Tips highlight that argenx holds more cash than debt on its balance sheet, indicating a strong financial position to support its ongoing research and development efforts. This is crucial as the company continues to advance its pipeline, including the Phase 3 trials for Empasiprubart and other potential treatments mentioned in the article.
Despite the positive revenue growth, an InvestingPro Tip notes that analysts do not anticipate the company to be profitable this year. This is consistent with the company's focus on expansion and pipeline development, as outlined in Stifel's analysis. The stock's trading near its 52-week high and its large price uptick over the last six months (46.93% total return) reflect investor confidence in argenx's potential, aligning with Stifel's bullish outlook and increased price target.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for argenx, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.